Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa.

Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R.

AIDS. 2009 Jan 28;23(3):335-42. doi: 10.1097/QAD.0b013e328321823f.

2.

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.

Lawn SD, Myer L, Edwards D, Bekker LG, Wood R.

AIDS. 2009 Aug 24;23(13):1717-25. doi: 10.1097/QAD.0b013e32832d3b6d.

4.

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.

Fox MP, Sanne IM, Conradie F, Zeinecker J, Orrell C, Ive P, Rassool M, Dehlinger M, van der Horst C, McIntyre J, Wood R.

AIDS. 2010 Aug 24;24(13):2041-50. doi: 10.1097/QAD.0b013e32833c703e.

5.
6.

Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa.

Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD.

PLoS One. 2013;8(2):e55824. doi: 10.1371/journal.pone.0055824. Epub 2013 Feb 13.

7.

The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.

Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA.

AIDS. 2002 Feb 15;16(3):359-67.

PMID:
11834947
8.

Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.

Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD.

PLoS One. 2012;7(3):e34156. doi: 10.1371/journal.pone.0034156. Epub 2012 Mar 30.

9.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
10.

Twelve-year mortality in adults initiating antiretroviral therapy in South Africa.

Cornell M, Johnson LF, Wood R, Tanser F, Fox MP, Prozesky H, Schomaker M, Egger M, Davies MA, Boulle A; International Epidemiology Databases to Evaluate AIDS-Southern Africa collaboration.

J Int AIDS Soc. 2017 Sep 25;20(1):21902. doi: 10.7448/IAS.20.1.21902.

11.

Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration.

PLoS Med. 2012;9(9):e1001304. Epub 2012 Sep 4.

12.

Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study.

Cornell M, Johnson LF, Schomaker M, Tanser F, Maskew M, Wood R, Prozesky H, Giddy J, Stinson K, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS-Southern Africa Collaboration.

Lancet HIV. 2015 Sep;2(9):e368-75. doi: 10.1016/S2352-3018(15)00113-7. Epub 2015 Aug 4.

13.

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.

Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD; ALLRT team.

AIDS. 2010 Jul 31;24(12):1867-76. doi: 10.1097/QAD.0b013e32833adbcf.

14.

Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting.

Clouse K, Pettifor A, Maskew M, Bassett J, Van Rie A, Gay C, Behets F, Sanne I, Fox MP.

AIDS. 2013 Feb 20;27(4):645-50. doi: 10.1097/QAD.0b013e32835c12f9.

15.

Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.

Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, Holmberg SD; HIV Outpatient Study Investigators.

Ann Intern Med. 2003 Apr 15;138(8):620-6.

PMID:
12693883
16.

Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.

ART-LINC of IeDEA Study Group, Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, Nash D, Jahn A, MacPhail P, Lüthy R, Wood R, Egger M.

AIDS. 2009 Sep 10;23(14):1867-74. doi: 10.1097/QAD.0b013e32832e05b2.

17.

HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies.

Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA).

J Int AIDS Soc. 2017 Jun 23;20(1):21327. doi: 10.7448/IAS.20.1.21327.

19.

Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.

Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.

AIDS. 2007 May 11;21(8):939-46.

PMID:
17457087
20.

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, Cameron PU, Petoumenos K, Lewin SR.

PLoS One. 2011;6(6):e20713. doi: 10.1371/journal.pone.0020713. Epub 2011 Jun 2.

Supplemental Content

Support Center